Patient characteristics
| . | Total cohort, n = 1079 . |
|---|---|
| Median age, y | |
| ≥60 | 883 |
| <60 | 196 |
| Male:female (ratio) | 682:397 (1.7) |
| Cases with follow-up, mo | 7.6 |
| Subtypes* | |
| MDS | |
| 5q− | 23 |
| RCUD | 57 |
| RARS | 68 |
| RCMD | 214 |
| RCMD-RS | 14 |
| MDS-U | 41 |
| RAEB-1 | 117 |
| RAEB-2 | 120 |
| Secondary AML† | 194 |
| MDS/MPN | |
| MDS/MPN-U | 54 |
| CMML-1 | 127 |
| CMML-2 | 28 |
| RARS-T | 22 |
| Cytogenetics,‡n (%) | |
| Normal karyotype | 392 (46) |
| Aberrant karyotype | 455 (55) |
| . | Total cohort, n = 1079 . |
|---|---|
| Median age, y | |
| ≥60 | 883 |
| <60 | 196 |
| Male:female (ratio) | 682:397 (1.7) |
| Cases with follow-up, mo | 7.6 |
| Subtypes* | |
| MDS | |
| 5q− | 23 |
| RCUD | 57 |
| RARS | 68 |
| RCMD | 214 |
| RCMD-RS | 14 |
| MDS-U | 41 |
| RAEB-1 | 117 |
| RAEB-2 | 120 |
| Secondary AML† | 194 |
| MDS/MPN | |
| MDS/MPN-U | 54 |
| CMML-1 | 127 |
| CMML-2 | 28 |
| RARS-T | 22 |
| Cytogenetics,‡n (%) | |
| Normal karyotype | 392 (46) |
| Aberrant karyotype | 455 (55) |
5q−, myelodysplastic syndrome with isolated del(5q); AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; RAEB, refractory anemia with excess blasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed sideroblasts; RCUD, refractory cytopenia with unilineage dysplasia.
WHO classification 2008.1
AML from MDS (n = 175), sAML from MDS/MPN (n = 19).
Cytogenetics data from 847 patients are available.